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Abstract
Background: Screening with prostate-specific antigen (PSA) test for prostate cancer is considered a preference
sensitive decision; meaning it does not only depend on what is best from a medical point of view, but also from a
patient value standpoint. Decision aids are evidence-based tools which are shown to help people feel clearer about
their values; therefore it has been advocated that decision aids should contain a specific values clarification method
(VCM). VCMs may be either implicit or explicit, but the evidence concerning the best method is scarce. We aim to
compare the perceived clarity of personal values in men considering PSA screening using decision aids with no
VCM versus an implicit VCM versus an explicit VCM.
Methods: Male factory employees from an industrial facility in the Northern region of Portugal aged 50 to 69 years
old will be randomly assigned to one of three decision aid groups used to support prostate cancer screening
decisions: (i) decision aid with information only (control), (ii) decision aid with information plus an implicit VCM, (iii)
decision aid with information plus an explicit VCM.
Men will be allowed release time from work to attend a session at their workplace. After a brief oral presentation,
those willing to participate in the study will fill the baseline questionnaire, plus a 5 point-Likert scale question about
intentions to undergo screening, and will then receive the intervention materials to complete.
We estimated a total sample size of 276 participants; with 92 in each group.
The primary outcome will be the perceived clarity of personal values assessed by the Portuguese validated
translation of the three subscales of the Decisional Conflict Scale. Secondary outcomes will be intention to be
screened (before and after the intervention), the total score from the Decisional Conflict Scale and the self-report of
having or not undergone screening at 6 months.
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Discussion: This study will add to the body of evidence on the role of decision aids to support health preference-
sensitive choices and provide further insight on the impact of different methods for eliciting people’s values
embedded within a decision aid.
Trial registration: NCT03988673 - clinicalTrials.gov (2019/06/17).
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Background
Prostate cancer is a leading cause of men cancer world-
wide [1]. Nevertheless, screening for prostate cancer
using a prostate specific antigen (PSA) test remains a
controversial issue; implying a trade-off between benefits
(mortality reduction, early diagnosis) and risks (high in-
stances of overdiagnosis and overtreatment in conjunc-
tion with the consequent side effects, as well as false
positive and false negative test results) [2, 3]. Thus, the
PSA test used to screen for prostate cancer is considered
a preference sensitive decision; meaning it does not only
depend on what is best from a medical point of view,
but also taking into account patient preferences; i.e., the
values a patient attaches to the advantages and disadvan-
tages of that option [4].
According to the International Patient Decision Aids
Standards (IPDAS) Collaboration, decision aids are
evidence-based tools designed to help people participate
in decision making about health care options with the
aim of improving the quality of the decision [5]. The
most recent systematic review concluded that decision
aids could increase patient knowledge about screening,
make people feel clearer about their values, reduce deci-
sional conflict, and promote an active patient role in de-
cision making [6].
In consideration of evidence on the role of decision
aids in helping to clarify patient values, the IPDAS
suggested that decision aids should include some
values clarification methods (VCMs) [7]. VCMs are
defined as strategies designed to help patients evalu-
ate the desirability and attributes of different options
in order to identify the option they prefer [8]. The
methods used for values clarification are often classi-
fied as being either implicit or explicit [9]. With im-
plicit techniques, patients are presented the pros and
cons of the available options, on a balance sheet, for
instance, and are expected to weigh up the desirabil-
ity of the different options on their own and, ultim-
ately, they will develop a preference for one of the
options [10]. On the other hand, explicit VCMs are
designed to engage the patient in tasks to specifically
compare the relative importance of characteristics
relevant to a decision [11]. Examples of such explicit
methods are rating and ranking tasks as well as social
matching which consists of viewing others engaged in
decision making and identifying one’s own values to
the values of these individuals [12].
In a previous version of the Cochrane review of patient
decision aids, 59.1% of the decision aids considered in-
cluded explicit methods used to clarify values. Decision
aids with explicit VCMs resulted in a higher proportion
of patients choosing a screening option congruent with
their values (RR = 1.51; 95% CI 1.17 to1.96; n = 13) in
comparison to a simple decision aid without explicit
values clarification or usual care [13]. Implicit VCMs
were not assessed in this review.
Nevertheless, there is still scarce evidence concerning
whether implicit and explicit values clarification
methods may make a difference on patient reported
values and preferences compared to instance where no
VCMs are used.
While engaging in an explicit values clarification task,
the patient may gain insight into the value he/she as-
signs to each option, which could help him/her to select
a preferred option and to be able to communicate his/
her preferences to others [10]. According to this ration-
ale, values clarification methods may be more helpful
when, in addition to helping users to realise what mat-
ters to them, they clarify how what matters to them de-
termines which option may be the preferred one [14].
On the other hand, explicitly exploring the pros and
cons of each option may increase uncertainty towards
the choice and, thus, implicit VCMs may be superior [9].
Objectives
To compare the perceived clarity of personal values in
men considering PSA screening using decision aids with
no VCMs versus an implicit VCM versus an explicit
VCM.
Trial design
Parallel three group (1:1:1) randomized controlled trial.
Methods
50 to 69-year-old male factory workers will be randomly
assigned to one of three decision aid groups supporting
prostate cancer screening decisions: (i) decision aid with
information only (Control), (ii) decision aid with infor-
mation plus an implicit VCM, and (iii) decision aid with
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information plus an explicit VCM. Figs 1 and 2 and
Table 1 summarize the main trial steps.
Study setting
The trial will be held at an industrial facility in the
Northern region of Portugal.
Eligibility criteria
To participate in the study, men should be aged 50 to
69 years, be at average risk for prostate cancer (e.g., no
personal or family history of prostate cancer; thus, not at
high risk), and be able to provide written informed con-
sent. Those unable to understand written Portuguese
will be excluded. The baseline questionnaire will assess
the participants’ eligibility.
Interventions
“Making the best choice” is an English language prostate
cancer printed screening decision aid which has been
rigorously developed [15] and extensively tested [16–19]
by a workgroup from Georgetown University (United
States of America). We were given permission to trans-
late and adapt the decision aid to the Portuguese popu-
lation. The decision aid includes different sections:
introduction to prostate and prostate cancer; screening
tests (results, benefits and risks); treatment (options,
benefits and risks); prostate cancer risk factors; encour-
agement to share decision-making with a physician; a
values clarification method; and resources to access add-
itional information (references and a glossary). KT, who
was the principal investigator of the original decision aid
is a co-investigator in this project. The results from the
translation and cultural adaptation of the decision aid to
the Portuguese population were recently published [20].
The testimonials section of the decision aid will be ex-
cluded in this study since this can be considered a type
of values clarification method and could thus bias the
results.
The VCM in the decision aid was adapted from a pre-
vious study [21] and is composed of 10 statements ad-
dressing the most important aspects involved in prostate
cancer screening decisions. The control group will re-
ceive the decision aid without any VCMs. One interven-
tion group will receive the decision aid with the implicit
VCM. In this version of the decision aid, men will be
presented with 10 statements. For the first set of five
statements, participants will be informed that “Men who
have made these statements often decide to get
screened” and for the second set of five statements, they
will be informed that “Men who have made these state-
ments often decide NOT to get screened.” The other
intervention group will receive the decision aid with an
explicit VCM. For each of the 10 statements, men will
be asked whether each sentence sounds like him or not.
Men will be asked their personal position towards
screening before and after reading the decision aid.
Outcomes
The primary outcome will be the perceived clarity of
personal values assessed by the Portuguese validated
Fig. 1 Randomisation of trial participants
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translation of the three subscales of the Decisional Con-
flict Scale (DCS) [22]. The Values Clarity subscores
range from 0 (feels extremely clear about personal values
for benefits and risks/side effects) to 100 (feels extremely
unclear about personal values); lower scores suggest bet-
ter clarity.
Secondary outcomes will be intention to be screened
and the total score from DCS. Respondents will be asked
a single question about their intention to undergo a PSA
screening, using a 5 point-Likert scale (ranging from
“strongly disagree” to “strongly agree”; intention to
undergo PSA screening will be considered positive if the
respondent replies with “agree” or “strongly agree”).
Total scores from the 16-questions DCS (including the
subscales values clarity, informed decision making, ef-
fective decision making, decision making support, deci-
sion making uncertainty) range from 0 (no decisional
conflict) to 100 (extremely high decisional conflict), dis-
criminating between those who make and delay deci-
sions [23]. Furthermore, prostate cancer screening status
at 6 months after the intervention will be assessed by
way of a self-report.
Patient timeline
After a brief oral presentation session, men willing to
participate in the study will be invited to stay and fill the
baseline questionnaire plus a 5 point-Likert scale ques-
tion about intention to undergo screening. These will
have the same numeric code as the sealed envelopes
containing the materials to be distributed. Participants
should then complete the required questions after inter-
vention assignment during the same session.
Table 1 Schedule of enrolment, interventions, and assessments
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT** -t1
2 weeks before
0
session
t1
session
t2
session
t3
session
t4
6months later
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
[Decision aid without VCM] X
[Decision aid with implicit VCM] X
[Decision aid with explicit VCM] X
ASSESSMENTS:
[baseline variables] X
[Screening intention] X X
[Decisional conflict scale] X
[Self-reported PSA screening] X
Fig. 2 Sequence of main trial steps
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Sample size
We estimated a total sample size of 276 participants, 92
in each group, using the ANOVA test for three groups
and considering an average effect size of 0.2 with a sig-
nificance level of 0.05 and 80% power, attending to the
psychometric properties of the DCS and also accounting
for 10% of participants leaving the study before
conclusion.
Recruitment
Two weeks in advance, male employees will be sent an
invitation letter to participate in a facultative session
about prostate cancer screening and presenting the trial
and how to participate. The session will be held at their
workplace, during business hours, and will be presented
by the lead investigator. During the session, men will be
invited to stay after the initial presentation if they are
willing to participate in the trial. They will then be pre-
sented with written information about the project, the
lead investigator will be available to answer any ques-
tions and the willing participants will be asked to give
their written consent. Men will be allowed release-time
from work to participate in the session.
Assignment of interventions, sequence generation and
blinding
To ensure allocation concealment, a computer-
generated random schedule (unstratified randomization
with a 1:1:1 allocation ratio) will be generated by a statis-
tician not otherwise involved in the trial. Blocking will
be reported in an appendix, even though all participants
will be randomized at the same time. The same statisti-
cian will prepare closed, equally sized, sequentially num-
bered, opaque, sealed white envelopes. The set of
envelopes will be given to the lead investigator which
will then distribute the envelopes to the participating
men.
Blinding
Due to the nature of the intervention, it will be impos-
sible to fully blind participants. In order to minimize
bias, participants will know that different formats of the
decision aid will be assessed, but they will not be in-
formed about the differences in formats or about the re-
search hypotheses. After the decision aid packages are
given to participants, the lead investigator will no longer
interact with participants; thus, she will not be aware of
which decision aid has been allocated to individual par-
ticipants. Data collection forms will be collected by other
members of the research team. Since the main outcome
is self-reported, it is impossible to blind outcome asses-
sors; however, data collection procedures will be the
same, regardless of the allocated group. The statistician
assessing the data and the first author will not be
blinded to allocation when analyzing or drafting the
manuscript, respectively.
Data collection methods
Baseline demographic data will be collected by way of
pre-intervention questionnaires. Participants will also
answer a 5-point Likert-scale question about intention
to be screened with PSA test.
Upon receiving the decision aid and, when applicable,
values clarification method reading/completion, partici-
pants will answer the post-intervention questionnaire,
containing the Portuguese validated translation of the
DCS, as well as the same above mentioned Likert-scale
question about intention to undergo PSA screening.
Data management
Participant paper files, only identifiable by a participant
ID number, will be stored in numerical order in a secure
place at the University of Porto. Participant paper files
will be maintained in storage for a period of 3 years after
completion of the study. All anonymized data will be en-
tered electronically and, only after all data has been en-
tered, will researchers contact the statistician who
prepared the randomization schedule to know which
group was assigned to individual participants access to
the study data will be restricted to the research team
based at University of Porto. A data tracking system with
time stamps will be implemented for audit purposes. A
password system will be utilized to control access to de-
identified electronic data and these passwords will be
changed every 3 months.
To ensure that we can follow participants for screen-
ing participation after 12 months, we will keep a single
file which links participant ID number to participant
name, phone number and one next of kin phone num-
ber. This electronic file will be kept by a team researcher
not based at the University of Porto.
Anonymized data will be analyzed on a personal com-
puter belonging to one of the authors based at the Uni-
versity of Porto.
Statistical methods
After collection, data will be analyzed using Microsoft
Excel 2016® and SPSS Statistics 25.0®. Participants will
be analyzed in the group they were randomized to,
regardless of actual intervention received. In order to
analyze between group differences concerning per-
ceived clarity of personal values, we will use One-way
ANOVA (if the variable distribution is normal) or
Kruskal-Wallis (if the variables are not distributed
normally). Normal distribution of variables will be
assessed by observing the respective histograms and
validated with the Kolmogorov-Smirnov test. For con-
tinuous variables with normal distributions, data will
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be described using mean (M), standard deviation
(SD), minimum (min), and maximum (max). For con-
tinuous variables not distributed normally, data will
be described using median (Med) and the respective
interquartile range [Q1; Q3]; Q1 being the first quar-
tile and Q3 being the third quartile.
If either the ANOVA or Kruskal-Wallis tests demon-
strates significant differences between groups, multiple
comparisons will be conducted between groups pairs in
order to detect between which groups there are
differences.
To test independence between categorical variables,
we will use Chi-square test for independence. Categor-
ical variables will be described using absolute and rela-
tive frequencies, N (%). p-values ≤0.05 will be considered
significant.
DCS total score is composed of 16 items (each one
with a 5-point Likert response scale) divided in five sub-
scores: uncertainty subscore (3 items), informed sub-
score (3 items), values clarity subscore (3 items), support
subscore (3 items), effective decision subscore (4 items).
For each participant partial scores and a total score will
be calculated. Concerning missing values, those partici-
pants who do not answer at least 50% of the items of
each subscale will be excluded from the analysis. The
total score will be presented on a 0–100 scale [23].
If there are baseline differences between groups, we
will perform multivariate analysis using linear multiple
regression.
Data monitoring
Given the expected safety during the trial, no data moni-
toring committee will be established or interim analyses
conducted.
Protocol amendments
In the case of substantive protocol amendments an ad-
dendum will be submitted both to Ethics Committee
and the Trial registry.
Consent
After adequate explanation on the study procedures and
aims by workgroup researchers and having the oppor-
tunity to discuss any questions or doubts with them,
participants will fill in a written consent form, if they are
willing to participate in the trial.
Confidentiality
All the information related to the study will be stored
securely at the study site. All participant information will
be stored in locked file cabinets in areas with limited ac-
cess at the University of Porto. All records containing
identity elements, such as informed consent forms, will
be stored elsewhere, separate from study records, and
identifiable by a code number. All local databases will be
secured with password. Any document with information
that potentially links participant ID numbers to other
identifying information will be stored in a separate,
locked file in an area with limited access.
Dissemination policy
Results from this study will be disseminated in peer-
reviewed publications, conference presentations, reports,
and in a PhD thesis. There will be no publication restric-
tions. Authors will comply with ICMJE authorship cri-
teria. No professional writers will be used. The trial
protocol will be published in an open access journal.
Discussion
To our knowledge, this will be the first randomized con-
trolled trial comparing information only (no VMC) ver-
sus an implicit VCM versus an explicit VCM embedded
within a full decision aid to support the decisions of
men regarding prostate cancer screening with PSA.
This study will add to the body of evidence on the role
of decision aids to support health preference-sensitive
choices and provide further insight on the impact of dif-
ferent methods for eliciting people’s values embedded
within a decision aid.
By assessing those men who underwent PSA screening
6 months after the intervention, we will be able to evalu-
ate the effect of the different VCMs on the actual
decision.
Conducting our research at an industrial workplace ra-
ther than a clinical setting may be an opportunity to
reach less educated populations not usually included in
trials and which could probably benefit more from the
support of decision aids in decision-making. On the
other hand, this may also represent a limitation from
our study since the findings may not be generalizable to
other male populations. Contamination may be another
issue, particularly concerning the report of PSA test at 6
months, as men’s decision can be attributed to a wide
range of factors and not only those strictly related to the
study. Therefore, results should be interpreted with
caution.
Future works should focus on deepening our under-
standing on the role of different VCM methods within
decision aids in helping to clarify patient values and use
more distal outcomes.
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